Elizabeth Claus, PhD, MD
Professor of Biostatistics; Director of Medical Research, School of Public HealthDownloadHi-Res Photo
Cards
Appointments
Biostatistics
Primary
Neurosurgery
Secondary
Contact Info
Biostatistics
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
About
Titles
Professor of Biostatistics; Director of Medical Research, School of Public Health
Biography
Elizabeth B. Claus, MD, PhD is Professor and Director of Medical Research in the Yale University School of Public Health as well as Attending Neurosurgeon and Director of Stereotactic Radiosurgery within the Department of Neurosurgery at Brigham and Women’s Hospital in Boston. She is a member of the board of advisors for the Acoustic Neuroma Association (ANA) as well as the Central Brain Tumor Registry of the United States (CBTRUS). Dr. Claus' work is focused in cancer and genetic epidemiology with an emphasis on the development of risk models for breast and brain tumors. She is the overall PI of the Meningioma Consortium, the Meningioma Genome-Wide Association Study, and the Yale Acoustic Neuroma Study as well as a co-investigator of the GLIOGENE (Genes for Glioma) and International Glioma Case/Control (GICC) projects. In addition to her research activities, Dr. Claus is a Board-certified neurosurgeon who completed her residency in neurosurgery at Yale-New Haven Hospital and her fellowship in neurosurgical oncology at Brigham and Women’s Hospital. Her clinical focus is on the treatment of meningioma, glioma, acoustic neuroma and brain metastases.
Claus launched the International Low-Grade Glioma (LGG) Registry in 2016 to discover why some people develop LGG, a slow growing but malignant brain tumor primarily affecting young adults, while others do not. The goal of the registry is also to learn more about the effect of this diagnosis and the associated treatments on daily life including the ability to work, drive, sleep, exercise, or take care of oneself and/or a family member. Recently Dr. Claus and a team of fellow scientists received funds from the National Cancer Institute to investigate the molecular evolution of LGG. The project, OPTimIzing engageMent in discovery of molecular evolution of low grade glioma” or OPTIMUM, will enroll 500 participants diagnosed with LGG and who have had two or more surgeries for their glioma and genotype these tumors to establish a comprehensive genomic characterization of the glioma tumors across time.
Appointments
Biostatistics
ProfessorPrimaryNeurosurgery
ProfessorSecondary
Other Departments & Organizations
- Biostatistics
- Biostatistics
- Cancer Prevention and Control
- Neurosurgery
- Obesity Research Working Group
- Yale Cancer Center
- Yale Center for Genomic Health
- Yale School of Public Health
- Yale School of Public Health - NEW
- Yale Ventures
Education & Training
- Fellow
- Brigham and Women's Hospital (2003)
- Resident
- Yale-New Haven Hospital (2002)
- Resident
- Yale- New Haven Hospital (1996)
- MD
- Yale University School of Medicine (1994)
- PhD
- Yale University (1988)
Research
Overview
- The Yale Breast Study
- The DCIS and BRCA1/2 Cohort Study
- The Meningioma Consortium Project
- The Meningioma Family Study
- The Meningioma Genome-Wide Association Study
- GLIOGENE (Genes for Glioma)
- The International Glioma Case/Control Study (GICC)
- The Yale Acoustic Neuroma Study (acousticneuroma@yale.edu)
- The International Low Grade Glioma Project (glioma@yale.edu)
Medical Research Interests
Astrocytoma; Breast Neoplasms; Central Nervous System Neoplasms; Epidemiology; Glioma; Meningioma; Neurosurgery; Oligodendroglioma; Statistics as Topic
Public Health Interests
Cancer; Genetics, Genomics, Epigenetics
Research at a Glance
Yale Co-Authors
Frequent collaborators of Elizabeth Claus's published research.
Publications Timeline
A big-picture view of Elizabeth Claus's research output by year.
Research Interests
Research topics Elizabeth Claus is interested in exploring.
Lisa Calvocoressi, PhD
Roel Verhaak, PhD
Samir Amin
Jeffrey Townsend, PhD
Lingeng Lu, MD, PhD
37Publications
3,563Citations
Glioma
Meningioma
Breast Neoplasms
Oligodendroglioma
Publications
2024
Canonical Amplifications and CDKN2A/B Loss Refine IDH1/2-mutant Astrocytoma Prognosis
Ghosh H, Patel R, Claus E, Castro L, Wen P, Ligon K, Meredith D, Bi W. Canonical Amplifications and CDKN2A/B Loss Refine IDH1/2-mutant Astrocytoma Prognosis. Neuro-Oncology 2024, noae258. PMID: 39584448, DOI: 10.1093/neuonc/noae258.Peer-Reviewed Original ResearchConceptsFocal gene amplificationsCDKN2A/B lossFocal amplificationGene amplificationAssociated with worse survivalAssociated with reduced survivalGrade 4 casesGrade 4 patientsLoss of CDKN2A/BMolecular featuresOverall survival predictionIntermediate prognosisTumor gradeWorse survivalIDH1/2-mutantShorter survivalHistological criteriaStratify riskPoor outcomeHistological featuresCDKN2A/BHomozygous lossAcademic medical centerGrade 2Glioma diagnosticsEPID-22. MUTATIONAL SIGNATURE ASSOCIATED WITH HALOALKANE EXPOSURE ENRICHED IN FIREFIGHTERS IN THE ADULT GLIOMA STUDY
Cannataro V, Bracci P, Taylor J, McCoy L, Rice T, Hansen H, Heffernan A, Wiemels J, Wiencke J, Wrensch M, Claus E. EPID-22. MUTATIONAL SIGNATURE ASSOCIATED WITH HALOALKANE EXPOSURE ENRICHED IN FIREFIGHTERS IN THE ADULT GLIOMA STUDY. Neuro-Oncology 2024, 26: viii142-viii142. PMCID: PMC11553659, DOI: 10.1093/neuonc/noae165.0558.Peer-Reviewed Original Research
2023
EPID-28. YEARS OF LIFE LOST FOR BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS IN THE UNITED STATES, 2018
Neff C, Price M, Gerstl J, Kruchko C, Barnholtz-Sloan J, Bernstock J, Smith T, Claus E, Ostrom Q. EPID-28. YEARS OF LIFE LOST FOR BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS IN THE UNITED STATES, 2018. Neuro-Oncology 2023, 25: v121-v121. PMCID: PMC10639734, DOI: 10.1093/neuonc/noad179.0460.Peer-Reviewed Original ResearchConceptsCentral nervous system tumorsNervous system tumorsTotal YLLYears of lifeSystem tumorsAtypical teratoid/rhabdoid tumorCancer-specific mortalityShorter survival timeNon-malignant tumorsCDC's National ProgramNational Vital Statistics SystemRace/ethnicityAge of deathNational burdenCancer morbidityVital Statistics SystemSpecific histopathologyRhabdoid tumorSurvival timeLife LostPremature deathTumorsYLLNational programMortality dataQOL-09. QUALITY OF LIFE AFTER SURGERY FOR LOWER GRADE GLIOMAS
Heffernan A, Wu Y, Benz L, Verhaak R, Kwan B, Claus E. QOL-09. QUALITY OF LIFE AFTER SURGERY FOR LOWER GRADE GLIOMAS. Neuro-Oncology 2023, 25: v250-v250. PMCID: PMC10639580, DOI: 10.1093/neuonc/noad179.0961.Peer-Reviewed Original ResearchConceptsLow-grade gliomasGrade gliomasNon-malignant brain tumoursShort Form Health SurveyBackground Limited dataForm Health SurveyGeneral healthy populationGroup of patientsMedical Outcomes StudyCase/control studyLong-term qualityTime of interviewResidents of ConnecticutQOL outcomesSample average ageHealth SurveyOutcome studiesMeningioma casesTreatment groupsBrain tumorsAverage ageControl studyHealthy populationControl populationPrime of life
2021
A molecularly integrated grade for meningioma
Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V, Greenwald NF, Nassiri F, Aldape K, Zadeh G, Choudhury A, Vasudevan HN, Magill ST, Raleigh DR, Abedalthagafi M, Aizer AA, Alexander BM, Ligon KL, Reardon DA, Wen PY, Al-Mefty O, Ligon AH, Dubuc AM, Beroukhim R, Claus EB, Dunn IF, Santagata S, Bi W. A molecularly integrated grade for meningioma. Neuro-Oncology 2021, 24: 796-808. PMID: 34508644, PMCID: PMC9071299, DOI: 10.1093/neuonc/noab213.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMeningioma patientsWHO gradeGrading systemCommon primary intracranial tumorWorld Health Organization gradeProgression-free survivalAdditional prognostic informationPrimary intracranial tumorsCox proportional hazardsGrading schemeTime-dependent areaSurgical resectionChromosomal copy-number dataClinical behaviorHistopathology featuresPrognostic informationPatient managementIntracranial tumorsDiscovery cohortClinical careIndependent cohortMitotic countPatientsProportional hazardsMeningiomasEnvironmental and sex-specific molecular signatures of glioma causation
Claus EB, Cannataro VL, Gaffney SG, Townsend JP. Environmental and sex-specific molecular signatures of glioma causation. Neuro-Oncology 2021, 24: 29-36. PMID: 33942853, PMCID: PMC8730771, DOI: 10.1093/neuonc/noab103.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIDH wild-type tumorsWild-type tumorsEnvironmental risk factorsIDH-mutant tumorsRisk factorsCases of gliomaMolecular signaturesPIK3CA mutationsPossible risk exposuresMutation subtypesCancer effectsExogenous exposureAdult gliomasTumorsWhole-exome sequencing dataGliomasKinase domainMutational signaturesCancer-causing mutationsMalesFemalesNon-coding regionsPIK3R1SexCancer mutational signatures
2020
Brain Tumor Discussions on Twitter (#BTSM): Social Network Analysis
Feliciano JT, Salmi L, Blotner C, Hayden A, Nduom EK, Kwan BM, Katz MS, Claus EB. Brain Tumor Discussions on Twitter (#BTSM): Social Network Analysis. Journal Of Medical Internet Research 2020, 22: e22005. PMID: 33030435, PMCID: PMC7582142, DOI: 10.2196/22005.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2019
Longitudinal molecular trajectories of diffuse glioma in adults
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 2019, 576: 112-120. PMID: 31748746, PMCID: PMC6897368, DOI: 10.1038/s41586-019-1775-1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdult patientsDiffuse gliomasRecurrent gliomaOverall survivalPoor outcomeCurrent therapiesChromosome arms 1p/19qAcquired alterationsMajor subtypesTherapeutic resistanceGliomasGlioma developmentGene alterationsIDH mutationsGlioma subtypesPatientsHypermutator phenotypeDriver genesSubtypesClinical annotationSurvivalSubclonal selectionCell cycleAlterationsLittle evidenceEPID-23. PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA
Poisson L, Kouwenhoven M, Snyder J, Alfaro-Munoz K, Kaur M, Bates A, Verhaak R, Watts C, Zadeh G, Ormond D, Claus E, Khasraw M. EPID-23. PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA. Neuro-Oncology 2019, 21: vi79-vi79. PMCID: PMC6847827, DOI: 10.1093/neuonc/noz175.323.Peer-Reviewed Original ResearchCitationsConceptsAdult malignant gliomasCommon data elementsMalignant gliomasGlioma researchRetrospective chart abstractionLongitudinal studySmall patient populationMulti-center collaborationResearch Electronic Data Capture (REDCap) systemChart abstractionPatient demographicsClinical courseClinical featuresOngoing trialsClinical variablesPatient populationUncommon cancerMedical historyClinical dataTranslational studiesGlioma Longitudinal Analysis ConsortiumClinical standardsMultidisciplinary expertsConfirmatory studiesGliomasLack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis
Saunders CN, Cornish AJ, Kinnersley B, Law PJ, Claus EB, Il’yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Houlston RS. Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis. Neuro-Oncology 2019, 22: 207-215. PMID: 31665421, PMCID: PMC7442418, DOI: 10.1093/neuonc/noz209.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDensity lipoprotein cholesterolGlioma riskLipoprotein cholesterolRisk factorsHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMultiple potential risk factorsInsulin-like growth factor-1Modifiable risk factorsSystolic blood pressureBody mass indexPotential risk factorsSerum immunoglobulin E.Body fat percentageGrowth factor-1Risk of gliomaFatty acid levelsLack of associationMendelian randomisation analysisBlood pressureTotal cholesterolWaist circumferenceHemoglobin levelsInflammatory factorsMass index
Academic Achievements & Community Involvement
activity National Institutes of Health
Peer Review Groups and Grant Study SectionsBoard MemberDetailsProvide advice to NIH relative to the Cancer Post-GWAS Initiative09/01/2010 - Presenthonor Population Science Research Prize
Yale School of Medicine AwardYale Cancer CenterDetails03/24/2022United Stateshonor Top 100 Publications, Yale Centennial
Yale University AwardSchool of Public Health, Yale UniversityDetails10/01/2015United Statesactivity Acoustic Neuroma Association
Public ServiceBoard MemberDetailsTo advise the ANA on a variety of topics related to the occurrence and treatment of acoustic neuroma10/01/2010 - 09/30/2015activity Glioma Research Consortium
ResearchDetails01/01/2008 - PresentDenmark; United Kingdom; Israel +2 moreAbstract/SynopsisProfessor Claus is a co-investigator for GLIOGENE, an international, multidisciplinary consortium of glioma researchers. The goal of this consortium is to identify susceptibility genes in high-risk familial brain tumor pedigrees by screening glioma patients within the United States, Europe, and Israel. The hypothesis is that there are specific discoverable genotypes that increase the risk of developing brain tumors. Professor Claus also conducts work with this group to refine treatment algorithms for patients diagnosed with low-grade gliomas.
News & Links
Media
- This first issue of the magazine focused on brain tumor epidemiology at the Yale School of Public Health
News
- May 02, 2024Source: Salud America!
7 Things You Should Know About Brain Tumors
- April 12, 2024
Yale Cancer Center Faculty and Trainees Present at AACR Annual Meeting
- March 18, 2024
Yale Cancer Center Experts Present New Research on Obesity, Tobacco, Evolution, and Early Onset Cancers at Leading Oncology Conference
- August 24, 2023Source: National Cancer Institute
Engaging People with Low-Grade Glioma in Cancer Research
Get In Touch
Contacts
Academic Office Number
Appointment Number
Office Fax Number
Clinic Fax Number
Mailing Address
Biostatistics
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
Administrative Support
Locations
60 College Street
Academic Office
Ste 205
New Haven, CT 06510